Back

Effect of sodium-glucose cotransporter-2 inhibitor (SGLT2-i) in patients with LVAD: a systematic review and meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diabetes, obesity, and the heart Diuretics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Elfatih A Hasabo

Galway (Ireland)

6 More presentations in this session

Presentation thumbnail
Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study
Doctor A. Alhakak (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis
Doctor K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis
Doctor P. Theofilis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease
Doctor J. Tjerkaski (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
Doctor E. Rodrigues (Botucatu, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes, obesity, and the heart

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis
thumbnail
Congress Presentation
The use of SGLT-2 inhibitors and hemoconcentration in patients with heart failure
thumbnail
Congress Presentation
The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources